Novartis Ag NVS
NYSE NVS
$158.86 +2.62 (+1.68%)
At close: Aug 21, 2026 · 4:00 PM EDT

Novartis Ag (NVS) Income from Non-Controlling Interests (2009 - 2026)

Novartis Ag (NVS) posted Income from Non-Controlling Interests of -$7.0 million for Q2 2026, down 40.0% sequentially from -$5.0 million in Q4 2025, and up 58.82% YoY from -$4.4 million in Q2 2025.

Novartis Ag (NVS) Income from Non-Controlling Interests (2009 - 2026) Analysis & Trends

Novartis Ag has reported Income from Non-Controlling Interests for 18 years, with the latest figure at -$7.0 million in Q2 2026.

  • Quarterly Income from Non-Controlling Interests rose 58.82% year-over-year to -$7.0 million in Q2 2026, while the trailing twelve-month figure through Jun 2026 was -$10.0 million (up 37.5% YoY) and the FY2025 annual result came in at -$17.0 million, down 750.0% from the prior year.
  • Income from Non-Controlling Interests slipped to -$7.0 million in Q2 2026 per NVS's latest filing, from -$5.0 million in the prior quarter.
  • Over five years, Income from Non-Controlling Interests peaked at $3.0 million in Q1 2025 and troughed at -$17.0 million in Q2 2025.
  • A 5-year average of -$1.5 million and a median of $1.0 million in 2022 frame the typical range for Income from Non-Controlling Interests.
  • The sharpest annual moves came in 2022 and 2025: Income from Non-Controlling Interests jumped 200.0% in 2022, then slumped 350.0% in 2025.
  • Over 5 years, Income from Non-Controlling Interests stood at -$2.0 million in 2022, then surged by 200.0% to $2.0 million in 2023, then changed by 0.0% to $2.0 million in 2024, then plunged by 350.0% to -$5.0 million in 2025, then sank by 40.0% to -$7.0 million in 2026.
  • According to Business Quant data, Income from Non-Controlling Interests over the past three periods registered -$7.0 million, -$5.0 million, and $2.0 million for Q2 2026, Q4 2025, and Q3 2025 respectively.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Inc. Minority (Qtr)
1 Johnson & Johnson 652.20 Bn 631.44 Bn 17.26 Bn -
2 AbbVie 469.51 Bn 462.94 Bn 12.70 Bn 3.00 Mn
3 Merck 376.81 Bn 369.67 Bn 12.21 Bn -2.00 Mn
4 Novartis Ag 303.04 Bn 295.35 Bn 11.24 Bn -7.00 Mn
5 Astrazeneca 257.61 Bn 252.71 Bn 12.86 Bn 1.00 Mn
6 Amgen 237.37 Bn 223.38 Bn 7.24 Bn -
7 Gilead Sciences 181.73 Bn 178.55 Bn 6.22 Bn -
8 Pfizer 159.66 Bn 147.96 Bn 10.94 Bn 10.00 Mn
9 Gsk 106.24 Bn 102.07 Bn 8.24 Bn 741.95 Mn
10 Sanofi 55.07 Bn 47.69 Bn 10.79 Bn 39.52 Mn

Historic Data

Download Data
DateValue
Jun 30, 2026 -7.00 Mn
Dec 31, 2025 -5.00 Mn
Sep 30, 2025 2.00 Mn
Jun 30, 2025 -17.00 Mn
Mar 31, 2025 3.00 Mn
Dec 31, 2024 2.00 Mn
Sep 30, 2024 -4.00 Mn
Dec 31, 2023 2.00 Mn
Sep 30, 2023 2.00 Mn
Jun 30, 2023 1.00 Mn
Mar 31, 2023 1.00 Mn
Dec 31, 2022 -2.00 Mn
Sep 30, 2022 2.00 Mn
Jun 30, 2022 1.00 Mn
Mar 31, 2022 -3.00 Mn
Dec 31, 2021 -2.00 Mn
Jun 30, 2021 -1.00 Mn
Dec 31, 2020 5.00 Mn
Sep 30, 2020 -3.00 Mn
Mar 31, 2020 -3.00 Mn